肝移植作为治疗肝周胆管癌的替代方案:评论性综述

IF 3.6 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Hepatobiliary & Pancreatic Diseases International Pub Date : 2024-01-20 DOI:10.1016/j.hbpd.2024.01.003
Wellington Andraus, Francisco Tustumi, Alexandre Chagas Santana, Rafael Soares Nunes Pinheiro, Daniel Reis Waisberg, Liliana Ducatti Lopes, Rubens Macedo Arantes, Vinicius Rocha Santos, Rodrigo Bronze de Martino, Luiz Augusto Carneiro D'Albuquerque
{"title":"肝移植作为治疗肝周胆管癌的替代方案:评论性综述","authors":"Wellington Andraus,&nbsp;Francisco Tustumi,&nbsp;Alexandre Chagas Santana,&nbsp;Rafael Soares Nunes Pinheiro,&nbsp;Daniel Reis Waisberg,&nbsp;Liliana Ducatti Lopes,&nbsp;Rubens Macedo Arantes,&nbsp;Vinicius Rocha Santos,&nbsp;Rodrigo Bronze de Martino,&nbsp;Luiz Augusto Carneiro D'Albuquerque","doi":"10.1016/j.hbpd.2024.01.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span>Perihilar cholangiocarcinoma (phCCC) is a dismal </span>malignancy<span><span>. There is no consensus regarding the best treatment for patients with unresectable phCCC. The present review aimed to gather the current pieces of evidence for </span>liver transplantation<span> and liver resection as a treatment for phCCC and to build better guidance for clinical practice.</span></span></p></div><div><h3>Data sources</h3><p>The search was conducted in PubMed, Embase, Cochrane, and LILACS. The related references were searched manually. Inclusion criteria were: reports in English or Portuguese literature that a) patients with confirmed diagnosis of phCCC; b) patients treated with a curative intent; c) patients with the outcomes of liver resection and liver transplantation. Case reports, reviews, letters, editorials, conference abstracts and papers with full-text unavailability were excluded from the analysis.</p></div><div><h3>Results</h3><p><span>Most of the current literature is based on observational retrospective studies with low grades of evidence. Liver resection has better long-term outcomes than systemic chemotherapy or palliation<span> therapy and liver transplantation is a good alternative for selected patients with unresectable phCCC. All candidates for resection or transplantation should be medically fit and free of intrahepatic or extrahepatic diseases. As a general rule, patients presenting with a tumor having a longitudinal size &gt; 3 cm or extending below the cystic duct, </span></span>lymph node disease<span>, confirmed extrahepatic dissemination; intraoperatively diagnosed metastatic disease<span>; a history of other malignancies within the last five years, and did not complete chemoradiation regimen and were medically unfit should not be considered for transplantation. Some of these criteria should be individually assessed. Liver transplantation or resection should only be considered in highly experienced hepatobiliary centers, and any decision-making must be based on a multidisciplinary evaluation.</span></span></p></div><div><h3>Conclusions</h3><p>phCCC is a complex condition with high morbidity. Surgical therapies, including hepatectomy and liver transplantation, are the best option for better long-term disease-free survival.</p></div>","PeriodicalId":55059,"journal":{"name":"Hepatobiliary & Pancreatic Diseases International","volume":"23 2","pages":"Pages 139-145"},"PeriodicalIF":3.6000,"publicationDate":"2024-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Liver transplantation as an alternative for the treatment of perihilar cholangiocarcinoma: A critical review\",\"authors\":\"Wellington Andraus,&nbsp;Francisco Tustumi,&nbsp;Alexandre Chagas Santana,&nbsp;Rafael Soares Nunes Pinheiro,&nbsp;Daniel Reis Waisberg,&nbsp;Liliana Ducatti Lopes,&nbsp;Rubens Macedo Arantes,&nbsp;Vinicius Rocha Santos,&nbsp;Rodrigo Bronze de Martino,&nbsp;Luiz Augusto Carneiro D'Albuquerque\",\"doi\":\"10.1016/j.hbpd.2024.01.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p><span>Perihilar cholangiocarcinoma (phCCC) is a dismal </span>malignancy<span><span>. There is no consensus regarding the best treatment for patients with unresectable phCCC. The present review aimed to gather the current pieces of evidence for </span>liver transplantation<span> and liver resection as a treatment for phCCC and to build better guidance for clinical practice.</span></span></p></div><div><h3>Data sources</h3><p>The search was conducted in PubMed, Embase, Cochrane, and LILACS. The related references were searched manually. Inclusion criteria were: reports in English or Portuguese literature that a) patients with confirmed diagnosis of phCCC; b) patients treated with a curative intent; c) patients with the outcomes of liver resection and liver transplantation. Case reports, reviews, letters, editorials, conference abstracts and papers with full-text unavailability were excluded from the analysis.</p></div><div><h3>Results</h3><p><span>Most of the current literature is based on observational retrospective studies with low grades of evidence. Liver resection has better long-term outcomes than systemic chemotherapy or palliation<span> therapy and liver transplantation is a good alternative for selected patients with unresectable phCCC. All candidates for resection or transplantation should be medically fit and free of intrahepatic or extrahepatic diseases. As a general rule, patients presenting with a tumor having a longitudinal size &gt; 3 cm or extending below the cystic duct, </span></span>lymph node disease<span>, confirmed extrahepatic dissemination; intraoperatively diagnosed metastatic disease<span>; a history of other malignancies within the last five years, and did not complete chemoradiation regimen and were medically unfit should not be considered for transplantation. Some of these criteria should be individually assessed. Liver transplantation or resection should only be considered in highly experienced hepatobiliary centers, and any decision-making must be based on a multidisciplinary evaluation.</span></span></p></div><div><h3>Conclusions</h3><p>phCCC is a complex condition with high morbidity. Surgical therapies, including hepatectomy and liver transplantation, are the best option for better long-term disease-free survival.</p></div>\",\"PeriodicalId\":55059,\"journal\":{\"name\":\"Hepatobiliary & Pancreatic Diseases International\",\"volume\":\"23 2\",\"pages\":\"Pages 139-145\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatobiliary & Pancreatic Diseases International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1499387224000031\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatobiliary & Pancreatic Diseases International","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1499387224000031","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景肝周胆管癌(phCCC)是一种令人沮丧的恶性肿瘤。对于无法切除的 phCCC 患者的最佳治疗方法,目前尚无共识。本综述旨在收集肝移植和肝切除术治疗 phCCC 的现有证据,为临床实践提供更好的指导。数据来源在 PubMed、Embase、Cochrane 和 LILACS 中进行了检索。人工检索了相关参考文献。纳入标准为:英语或葡萄牙语文献中关于以下内容的报告:a)确诊为咽癌变的患者;b)以治愈为目的进行治疗的患者;c)肝切除和肝移植结果的患者。病例报告、综述、信件、社论、会议摘要以及无法获得全文的论文均未纳入分析范围。与全身化疗或姑息治疗相比,肝切除术的长期疗效更好,而肝移植则是部分无法切除的咽癌变患者的良好选择。所有接受切除或移植手术的患者都应身体健康,没有肝内或肝外疾病。一般来说,肿瘤纵向大小超过 3 厘米或延伸至囊管以下、淋巴结病变、确诊肝外播散、术中确诊转移性疾病、近五年内有其他恶性肿瘤病史、未完成化疗且身体状况不佳的患者不应考虑移植。其中一些标准应单独评估。只有在经验丰富的肝胆中心才能考虑肝移植或切除,而且任何决策都必须基于多学科评估。包括肝切除术和肝移植在内的外科疗法是提高长期无病生存率的最佳选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Liver transplantation as an alternative for the treatment of perihilar cholangiocarcinoma: A critical review

Background

Perihilar cholangiocarcinoma (phCCC) is a dismal malignancy. There is no consensus regarding the best treatment for patients with unresectable phCCC. The present review aimed to gather the current pieces of evidence for liver transplantation and liver resection as a treatment for phCCC and to build better guidance for clinical practice.

Data sources

The search was conducted in PubMed, Embase, Cochrane, and LILACS. The related references were searched manually. Inclusion criteria were: reports in English or Portuguese literature that a) patients with confirmed diagnosis of phCCC; b) patients treated with a curative intent; c) patients with the outcomes of liver resection and liver transplantation. Case reports, reviews, letters, editorials, conference abstracts and papers with full-text unavailability were excluded from the analysis.

Results

Most of the current literature is based on observational retrospective studies with low grades of evidence. Liver resection has better long-term outcomes than systemic chemotherapy or palliation therapy and liver transplantation is a good alternative for selected patients with unresectable phCCC. All candidates for resection or transplantation should be medically fit and free of intrahepatic or extrahepatic diseases. As a general rule, patients presenting with a tumor having a longitudinal size > 3 cm or extending below the cystic duct, lymph node disease, confirmed extrahepatic dissemination; intraoperatively diagnosed metastatic disease; a history of other malignancies within the last five years, and did not complete chemoradiation regimen and were medically unfit should not be considered for transplantation. Some of these criteria should be individually assessed. Liver transplantation or resection should only be considered in highly experienced hepatobiliary centers, and any decision-making must be based on a multidisciplinary evaluation.

Conclusions

phCCC is a complex condition with high morbidity. Surgical therapies, including hepatectomy and liver transplantation, are the best option for better long-term disease-free survival.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.40
自引率
6.10%
发文量
152
审稿时长
3.0 months
期刊介绍: Hepatobiliary & Pancreatic Diseases International (HBPD INT) (ISSN 1499-3872 / CN 33-1391/R) a bimonthly journal published by First Affiliated Hospital, Zhejiang University School of Medicine, China. It publishes peer-reviewed original papers, reviews and editorials concerned with clinical practice and research in the fields of hepatobiliary and pancreatic diseases. Papers cover the medical, surgical, radiological, pathological, biochemical, physiological and historical aspects of the subject areas under the headings Liver, Biliary, Pancreas, Transplantation, Research, Special Reports, Editorials, Review Articles, Brief Communications, Clinical Summary, Clinical Images and Case Reports. It also deals with the basic sciences and experimental work. The journal is abstracted and indexed in SCI-E, IM/MEDLINE, EMBASE/EM, CA, Scopus, ScienceDirect, etc.
期刊最新文献
Chinese contributions to liver transplantation. "No-donor" liver transplantation. No-touch recipient hepatectomy in liver transplantation for liver malignancies: A state-of-the-art review. Research progress of ischemia-free liver transplantation. Sequential living donor liver transplantation after liver resection optimizes outcomes for patients with high-risk hepatocellular carcinoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1